Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitamin D3 (cholecalciferol) and acyclovir are being evaluated in a Phase 4 randomized, single-blinded clinical trial conducted by Cairo University for the treatment of plantar warts caused by human papillomavirus (HPV) infection. Vitamin D3 is a fat-soluble steroid prohormone that acts as an immunomodulator; it stimulates macrophages and cathelicidin production, inhibits cellular proliferation, and induces terminal differentiation. Acyclovir is a synthetic purine nucleoside analogue antiviral agent that selectively inhibits viral DNA replication. In this study context, both agents are administered via intralesional injection directly into the base of the warts to assess their comparative efficacy, safety, and recurrence rates.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitamin D3 + acyclovir.